Skip to contentP
Palvella Therapeutics, Inc.
P
PVLAPalvella Therapeutics, Inc. Q1 2019 · 10-Q
Revenue$7.53M$7.53M+118.8% vs Q1 2018 Net Income-$10.35M-$10.35MN/M vs Q1 2018 EPS Diluted-$0.20-$0.20N/M vs Q1 2018 Operating Income-$10,683,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Palvella Therapeutics, Inc. · CIK 1583648 · Engraved from SEC EDGAR
Free Cash Flowderived-$15,229,000N/M Margins · derivedOperating margin-141.8%+94.4 pt vs Q1 2018
Net margin-137.4%+115.7 pt vs Q1 2018
ended Mar 31, 2019 · filed May 10, 2019 · 40 d after period end